8-K: Pacira BioSciences Reports Solid Q2 2024 Results, Prepares for Reimbursement Milestone

Pacira BioSciences announced its second quarter 2024 financial results, highlighting revenue growth and strategic preparations for a key reimbursement change in 2025.

Summary

• Pacira BioSciences reported total revenues of $178.0 million for the second quarter of 2024, an increase from $169.5 million in the same period last year.
• Net product sales were $136.9 million for EXPAREL, $30.7 million for ZILRETTA, and $5.7 million for iovera.
• The company achieved a net income of $18.9 million, or $0.41 per share basic and $0.39 per share diluted.
• Adjusted EBITDA for the quarter was $62.1 million.
• Pacira is preparing for the implementation of the NOPAIN Act in January 2025, which will provide separate reimbursement for EXPAREL in outpatient procedures.
• The company has initiated a $150 million share repurchase program and issued $287.5 million in convertible senior notes due 2029.
• Pacira is reiterating its full-year 2024 financial guidance, including total revenue of $680 million to $705 million.

Sentiment

Score: 7

Explanation: The sentiment is positive due to revenue growth, strategic initiatives, and a strong cash position. However, there are some concerns about increased operating expenses and a decrease in GAAP net income, which temper the overall positive outlook.

Positives

• Pacira saw revenue growth across all three of its key products: EXPAREL, ZILRETTA, and iovera.
• The company's adjusted EBITDA increased to $62.1 million, indicating improved profitability.
• The upcoming NOPAIN Act implementation is expected to drive increased EXPAREL utilization and revenue growth.
• The share repurchase program and debt refinancing demonstrate proactive capital management.
• Pacira ended the quarter with a strong cash position of $404.2 million.

Negatives

• GAAP net income decreased to $18.9 million from $25.8 million in the same quarter last year.
• Total operating expenses increased to $149.8 million from $129.6 million year-over-year.
• EXPAREL sales growth was partially offset by contracted discounts and vial mix.
• Research and development expenses increased to $20.3 million from $18.8 million year-over-year.

Risks

• The finalization of the proposed CMS rule for separate EXPAREL reimbursement is still pending.
• The company's success is dependent on the market acceptance of EXPAREL, ZILRETTA, and iovera.
• There are risks associated with the integration of acquisitions and the company's manufacturing and supply chain.
• The company is exposed to global and U.S. economic conditions, including inflation and rising interest rates.
• There are risks associated with the company's debt obligations.

Future Outlook

Pacira anticipates accelerated topline growth in 2025 and beyond due to the implementation of separate EXPAREL reimbursement for outpatient procedures under the NOPAIN Act. The company is focused on maximizing the benefits of this reimbursement change and driving awareness of its opioid-sparing products.

Management Comments

• Frank D. Lee, chief executive officer of Pacira BioSciences, stated that the first half of the year was marked by meaningful progress towards commercial, clinical, and business objectives.
• Mr. Lee also mentioned that the company maintained solid sales across all three opioid-sparing products, strengthened the balance sheet, and realigned the leadership team.
• Mr. Lee expressed confidence that the NOPAIN Act reimbursement milestone will drive expanded EXPAREL utilization and accelerated topline growth.

Industry Context

This announcement comes as the healthcare industry is increasingly focused on non-opioid pain management solutions. The implementation of the NOPAIN Act and the proposed separate reimbursement for EXPAREL align with this trend, potentially positioning Pacira as a leader in this space. The company's focus on commercial readiness and awareness campaigns also reflects the competitive landscape in the pharmaceutical and medical device sectors.

Comparison to Industry Standards

• Pacira's revenue growth in Q2 2024 is in line with other companies in the non-opioid pain management sector, such as Heron Therapeutics, which also reported growth in their respective product sales.
• The company's adjusted EBITDA of $62.1 million is comparable to other mid-sized pharmaceutical companies, indicating a healthy level of profitability.
• The share repurchase program and debt refinancing are common strategies used by companies to manage capital and improve shareholder value, similar to actions taken by companies like Collegium Pharmaceutical.
• The focus on the NOPAIN Act and separate reimbursement for EXPAREL is a unique opportunity for Pacira, as it is one of the few companies with a product that qualifies for this reimbursement, giving it a competitive advantage over companies that do not have products that qualify for the NOPAIN act.

Stakeholder Impact

• Shareholders may benefit from the share repurchase program and potential future growth.
• Employees may be impacted by the restructuring plan, but the company is focused on long-term success.
• Customers may benefit from increased access to non-opioid pain management options.
• Suppliers may see increased demand for Pacira's products.
• Creditors may be impacted by the company's debt refinancing.

Next Steps

• Pacira will continue to prepare for the implementation of the NOPAIN Act in January 2025.
• The company will focus on driving awareness of the opioid-sparing benefits of EXPAREL.
• Pacira will continue to execute its share repurchase program.
• The company will continue to invest in research and development.

Key Dates

Keywords

EXPAREL, ZILRETTA, iovera, Non-Opioid Pain Management, Reimbursement, NOPAIN Act, Share Repurchase, Convertible Notes, EBITDA, Financial Results